New principles of cancer therapy give new hope for oncological patients Nobel Prize in Physiology and Medicine 2018

被引:11
作者
Bernadic, M., Jr. [1 ,2 ]
Duchon, R. [1 ,2 ]
Aziri, R. [1 ,2 ]
Mladosievicova, B. [3 ]
机构
[1] NCI, Dept Surg Oncol, Klenova 1, SK-83310 Bratislava, Slovakia
[2] Slovak Med Univ, Klenova 1, SK-83310 Bratislava, Slovakia
[3] Comenius Univ, Sch Med, Dept Pathophysiol, Bratislava, Slovakia
来源
BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY | 2019年 / 120卷 / 01期
关键词
Nobel Prize; physiology; medicine; immune system; inhibition; cancer therapy; PD-1; BLOCKADE; IMMUNOTHERAPY; MEMBER;
D O I
10.4149/BLL_2019_002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The Nobel Prize in Physiology or Medicine 2018 was awarded jointly to James P. Allison and Tasuku Honjo, for their discovery of cancer therapy by inhibition of negative immune regulation". A number of therapeutic approaches are available for cancer treatment, including surgery, radiation, and other strategies, some of which have been awarded previous Nobel Prizes. These include methods for hormone treatment for prostate cancer (Huggins, 1966), chemotherapy (Elion and Hitchins, 1988), and bone marrow transplantation for leukemia (Thomas, 1990). Many scientists engaged in intense basic research and uncovered fundamental mechanisms regulating immunity and also showed how the immune system can recognize cancer cells. T-cells were shown to have receptors that bind to structures recognized as non-self and such interactions trigger the immune system to engage in defense. However, additional proteins acting as T-cell accelerators are also required to trigger a full-blown immune response. Many scientists contributed to this important basic research and identified other proteins that function as brakes on the T-cells, inhibiting immune activation. This intricate balance between the accelerators and inhibitors is essential for a tight control. New strategy was developed into a therapy for humans. Promising results soon emerged from several groups, and in 2010 an important clinical study showed striking effects in patients with advanced melanoma. In several patients, signs of remaining cancer disappeared. The results were dramatic, leading to long-term remission and possible cure in several patients with metastatic cancer, a condition that had previously been considered essentially untreatable. Such remarkable results had never been seen in this patient group before (Fig. 2, Ref. 12). Text in PDF www.elis.sk.
引用
收藏
页码:15 / 18
页数:4
相关论文
共 12 条
[1]   Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy [J].
Chowdhury, P. S. ;
Chamoto, K. ;
Honjo, T. .
JOURNAL OF INTERNAL MEDICINE, 2018, 283 (02) :110-120
[2]   Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation [J].
Freeman, GJ ;
Long, AJ ;
Iwai, Y ;
Bourque, K ;
Chernova, T ;
Nishimura, H ;
Fitz, LJ ;
Malenkovich, N ;
Okazaki, T ;
Byrne, MC ;
Horton, HF ;
Fouser, L ;
Carter, L ;
Ling, V ;
Bowman, MR ;
Carreno, BM ;
Collins, M ;
Wood, CR ;
Honjo, T .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (07) :1027-1034
[3]   Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients [J].
Hodi, FS ;
Mihm, MC ;
Soiffer, RJ ;
Haluska, FG ;
Butler, M ;
Seiden, MV ;
Davis, T ;
Henry-Spires, R ;
MacRae, S ;
Willman, A ;
Padera, R ;
Jaklitsch, MT ;
Shankar, S ;
Chen, TC ;
Korman, A ;
Allison, JP ;
Dranoff, G .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (08) :4712-4717
[4]   INDUCED EXPRESSION OF PD-1, A NOVEL MEMBER OF THE IMMUNOGLOBULIN GENE SUPERFAMILY, UPON PROGRAMMED CELL-DEATH [J].
ISHIDA, Y ;
AGATA, Y ;
SHIBAHARA, K ;
HONJO, T .
EMBO JOURNAL, 1992, 11 (11) :3887-3895
[5]   PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells [J].
Iwai, Y ;
Terawaki, S ;
Honjo, T .
INTERNATIONAL IMMUNOLOGY, 2005, 17 (02) :133-144
[6]  
Kausitz J, 2014, NADOROVE MARKERY
[7]   Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer [J].
Kwon, ED ;
Hurwitz, AA ;
Foster, BA ;
Madias, C ;
Feldhaus, AL ;
Greenberg, NM ;
Burg, MB ;
Allison, JP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (15) :8099-8103
[8]   Enhancement of antitumor immunity by CTLA-4 blockade [J].
Leach, DR ;
Krummel, MF ;
Allison, JP .
SCIENCE, 1996, 271 (5256) :1734-1736
[9]   Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor [J].
Nishimura, H ;
Nose, M ;
Hiai, H ;
Minato, N ;
Honjo, T .
IMMUNITY, 1999, 11 (02) :141-151
[10]   Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists [J].
Peggs, K. S. ;
Quezada, S. A. ;
Allison, J. P. .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2009, 157 (01) :9-19